Athira Pharma: Data shows fosgonimeton treatment significantly improved NfL

Athira Pharma announced the presentation of additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease at the 15th Clinical Trials on Alzheimer’s Disease conference. The late-breaking poster presentation highlights the effect of fosgonimeton treatment on biomarkers associated with neurodegeneration, neuroinflammation, and Alzheimer’s specific protein pathologies. Key findings from the presentation include: Baseline NfL levels may predict functional decline in patients with mild-to-moderate AD as assessed by the change from baseline measures of ADCS-ADL23. Fosgonimeton treatment significantly reduced levels of NfL and numerically reduced levels of GFAP and YKL-40. Fosgonimeton treatment showed directional improvements in biomarkers of AD-associated protein pathologies compared to placebo Fosgonimeton treatment-related reductions in NfL and GFAP significantly correlated with improvements in clinical outcomes, as assessed by the Global Statistical Test, a composite score of ADAS-Cog11 and ADCS-ADL23.